Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2385| Título : | Efficacy of a tetravalent dengue vaccine in children in Latin America |
| Creador: | Villar L |
| Nivel de acceso: | Open access |
| Palabras clave : | Adolescente Anticuerpos Antivirales - sangre niño Dengue - inmunología Dengue - prevención & control Dengue - virología Vacunas contra el Dengue - inmunología Virus del Dengue - genética Virus del Dengue - inmunología Virus del Dengue - aislamiento & purificación Enfermedades Endémicas - prevención & control Femenino Hospitalizacion Humanos Análisis de Intención de Tratar América Latina Masculino Serogrupo Índice de Severidad de la Enfermedad Método Simple-Ciego Resultado del Tratamiento Vacunas Atenuadas -inmunología Adolescent Antibodies, Viral - blood Child Dengue - immunology Dengue - prevention & control Dengue - virology Dengue Vaccines - immunology Dengue Virus - genetics Dengue Virus - immunology Dengue Virus - isolation & purification Endemic Diseases - prevention & control Female Hospitalizat1ion Humans Intention to Treat Analysis Latin America Male Serogroup Severity of Illness Index Single-Blind Method Treatment Outcome Vaccines, Attenuated - immunology Dengue Vacunas contra el Dengue Anticuerpos Antivirus Virus del Dengue Dengue Dengue Vaccines Antibodies, Viral Dengue Virus |
| Descripción : | immunogenicity subgroup of 1944 children had seropositive status for one or more dengue serotypes. In the per-protocol population, there were 176 VCD cases (with 11,793 person-years at risk) in the vaccine group and 221 VCD cases (with 5809 person-years at risk) in the control group, for a vaccine efficacy of 60.8% (95% confidence interval [CI], 52.0 to 68.0). In the intention-to-treat population (those who received at least one injection), vaccine efficacy was 64.7% (95% CI, 58.7 to 69.8). Serotype-specific vaccine efficacy was 50.3% for serotype 1, 42.3% for serotype 2, 74.0% for serotype 3, and 77.7% for serotype 4. Among the severe VCD cases, 1 of 12 was in the vaccine group, for an intention-to-treat vaccine efficacy of 95.5%. Vaccine efficacy against hospitalization for dengue was 80.3%. The safety profile for the CYD-TDV vaccine was similar to that for placebo, with no marked difference in rates of adverse events. Conclusions The CYD-TDV dengue vaccine was efficacious against VCD and severe VCD and led to fewer hospitalizations for VCD in five Latin American countries where dengue is endemic. (Funded by Sanofi Pasteur; ClinicalTrials.gov number, NCT01374516.) Copyright © 2015 Massachusetts Medical Society. All rights reserved. |
| Colaborador(es) u otros Autores: | Dayan Gh Arredondo-García JL Rivera DM Cunha R Deseda C Reynales H Costa MS Morales-Ramírez JO Carrasquilla G Rey LC Dietze R Luz K Rivas E Miranda Montoya MC Cortés Supelano M Zambrano B Langevin E Boaz M Tornieporth N Saville M Noriega F; Cyd15 Study Group. |
| Fecha de publicación : | 2015 |
| Tipo de publicación: | Artículo |
| Formato: | |
| Identificador del Recurso : | 10.1056/NEJMoa1411037 |
| Fuente: | New England Journal of Medicine 372(2):113 - 123 |
| URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2385 |
| Idioma: | eng |
| Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.